Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

NCT06510465 | Not Yet Recruiting Phase 2

• 1 other identifier: SHPD009
• Study Type: interventional
• Target: 143
• Locations: 1 country
• Sites: 2

Brief Summary

This study is a prospective, multi-center, single-arm, two-cohort, exploratory study, aiming to explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in breast cancer patients.

Conditions

Breast Cancer

Keywords

breast cancer; utidelone; cisplatin; neoadjuvant therapy

Outcome Measures

Primary Outcomes (1)

• pCR

  ypT0/is ypN0

  through surgery completion, an average of 16 weeks

Secondary Outcomes (16)

• breast pCR

  through surgery completion, an average of 16 weeks

• RCB 0/I rate

  through surgery completion, an average of 16 weeks

• RCB class

  through surgery completion, an average of 16 weeks

• Rate of lymph node negative

  through surgery completion, an average of 16 weeks

• ORR by physical examination

  After completing neoadjuvant therapy before surgery, an average of 16 weeks

Study Arms (2)

HER2 negative breast cancer cohort

EXPERIMENTAL

Human Epidermal Growth Factor Receptor 2 (HER2 ) negative breast cancer utidelone and cisplatin

Drug: utidelone; Drug: Cisplatin

HER2 positive breast cancer cohort

EXPERIMENTAL

Human Epidermal Growth Factor Receptor 2 (HER2 ) positive breast cancer utidelone，cisplatin，tratuzumab and pertuzumab (both Intravenous preparations or subcutaneous preparations can be used)

Drug: utidelone; Drug: Cisplatin; Drug: Trastuzumab; Drug: Pertuzumab

Interventions

utidelone DRUG

utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；

Also known as: UTD1

HER2 negative breast cancer cohort; HER2 positive breast cancer cohort

Cisplatin DRUG

cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.

Also known as: DDP

HER2 negative breast cancer cohort; HER2 positive breast cancer cohort

Trastuzumab DRUG

Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d

HER2 positive breast cancer cohort

Pertuzumab DRUG

Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase

HER2 positive breast cancer cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years old;
• Primary invasive breast cancer confirmed by pathology; Before neoadjuvant therapy, the primary breast lesion was larger than 2cm(cT2-T4a-d, according to the anatomical staging of AJCC 8th edition), or the clinical images of lymph nodes considered metastasis or pathologically confirmed metastasis (CN+); or patients whose primary breast lesions are more than 1cm and less than 2cm, and whose lymph nodes have not metastasized (cT1cN0) must meet one of the following conditions: hormone receptor negative, HER2 positive, or ki67 greater than 20%. If bilateral breast cancer is found at the same time, it can be admitted to the group, but it is necessary to determine which side of the lesion is to be evaluated before taking the drug;
• According to the RECIST version 1.1 standard (see Annex I), there is at least one measurable lesion before neoadjuvant therapy;
• The score of ECOG is 0 or 1;
• During neoadjuvant therapy, ovarian function suppression can be given at the same time;
• The hematological examination and blood biochemical examination should meet the following requirements: white blood cell count (WBC)≥3.0×109/L, neutrophil count (ANC)≥1.5×109/L and platelet count (PLT) ≥ 75× 109/L; Hemoglobin (HB) ≥ 80g/L; Total bilirubin (TBIL)≤1.5× upper limit of normal value (ULN), AST(sGOT), ALT(sGPT)≤2×ULN and creatinine (Cr) ≤ 1.5× ULN;
• creatinine clearance rate ≥50mL/min(Cockcroft-Gault formula);
• Subjects voluntarily joined the study, signed the informed consent form, and had good compliance and cooperated with the follow-up.

You may not qualify if:

• Patients during pregnancy and lactation, patients with fertility and positive baseline pregnancy test, or women of childbearing age who are unwilling to take effective contraceptive measures during the whole trial period;
• There is distant metastasis of breast cancer confirmed by imaging or pathology before enrollment;
• There is evidence of sensory or motor nerve diseases;
• Severe cardiopulmonary insufficiency, severe hepatic and renal insufficiency, severe concomitant disease or active infection, including known HIV infection;
• allergic to the research drug or its auxiliary materials;
• Arterial/venous thrombotic events, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, occurred within 6 months before the start of the study;
• Previous history of other malignant tumors, except the cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and the second primary malignant tumor with high 5-year recurrence-free survival rate determined by researchers;
• According to the researcher's judgment, there are accompanying diseases (including but not limited to uncontrollable hypertension, severe diabetes, active infection, thyroid disease, etc.) that seriously endanger the patient's safety or affect the patient's completion of the study, and any other circumstances that the researcher judges that the patient is not suitable for participating in this study.

Sponsors & Collaborators

• RenJi Hospital: lead

Study Sites (2)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, 200127, China

Location

Renji Hospital

Shanghai, China

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Cisplatin; Trastuzumab; pertuzumab

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 23, 2024
• First Posted: July 19, 2024
• Study Start: August 1, 2024
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): March 31, 2032
• Last Updated: July 19, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)